

**CURRICULUM VITAE
OREGON HEALTH & SCIENCE UNIVERSITY**

NAME	Jeffrey W. Tyner	DATE	06/08/2012
PRESENT POSITION AND ADDRESS			
Academic Rank:	Assistant Professor		
Department/ Division:	Cell & Developmental Biology		
Professional Address:	OHSU BRB 511 Mailcode L592 3181 SW Sam Jackson Park Road Portland, OR 97239		
E-Mail Address:	tynerj@ohsu.edu		
II. EDUCATION			

Undergraduate and Graduate (Include Year, Degree, and Institution):

1995-1999 B.A.
 Grinnell College
 Grinnell, IA, Major: Biology/Music

1999-2005 Ph.D., Molecular Cell Biology Program
 Division of Biology and Biomedical Science
 Washington University School of Medicine
 St. Louis, MO

Postgraduate (Include Year, Degree, and Institution):

2005-2010 Post-Doctoral Fellow with Dr. Brian J. Druker
 Division of Hematology/Oncology
 Oregon Health & Science University

III. PROFESSIONAL EXPERIENCE

Academic (Include Year, Position, and Institution):

2010-2012 Research Assistant Professor
 Department of Medicine, Division of Hematology/Oncology

2012-	<p>Oregon Health & Science University Knight Cancer Institute Assistant Professor Department of Cell & Developmental Biology Oregon Health & Science University Knight Cancer Institute</p>
-------	--

IV. SCHOLARSHIP

Area(s) of Research/Scholarly Interest:

Hematology/Oncology
Kinase Signaling
Genetics of Kinase Dysregulation
Targeted Therapies
Personalized Medicine

Grants and Contracts:

Federal (Include Title, Source, PI, Amount Period, and % Effort)

Title of Project or Subproject	Characterization of ROR1 Overexpression, Signaling, and Efficacy as a Therapeutic Target in t(1;19)-Positive Acute Lymphoblastic Leukemia
Source	NIH/NCI
Name of PI	Jeffrey W. Tyner
Role	PI
Grant Number	5K99CA151457-02
Annual Direct Costs	\$118,425
Dates of Proposed Project	9/1/10 – 8/31/15
% Effort	75%
Major Goals of Project	This project aims to investigate one gene target (ROR1) in great detail with analyses focusing on transcriptional regulation, signaling pathways, and development of novel therapeutics targeted at this specific gene.

Other Support (Include Title, Source, PI, Amount Period, and % Effort)

Title of Project or Subproject	Characterization of TNK1 Expression Patterns, Signaling and Efficacy as a Therapeutic Target in B- and T-cell Acute Lymphoblastic Leukemia
Source	William Lawrence and Blanche Hughes Foundation
Name of PI	Jeffrey W. Tyner
Role	PI
Grant Number	No Number
Annual Direct Costs	\$115,000
Dates of Proposed Project	1/1/11 - 12/31/14
% Effort	5%

Major Goals of Project	The major goal of this project is to identify the clinical and molecular characteristics that define sensitivity to inhibition of the gene target, TNK1, as well as identifying clinical candidate TNK1 inhibitors
------------------------	--

Title of Project or Subproject	Novel Tyrosine Kinase Targets in Leukemia and Myeloproliferative Neoplasms
Source	The Leukemia & Lymphoma Society
Name of PI	Brian J. Druker
Role	Co-Leader of Project 1; Leader of Core A
Grant Number	7005-11
Annual Direct Costs	\$1,042,000 (Tyner \$175,000)
Dates of Proposed Project	1/1/11 - 12/31/14
% Effort	15%
Major Goals of Project	The major goals of this collaborative Specialized Center of Research (SCOR) are to 1) identify novel kinase targets, 2) determine the mechanism underlying kinase activation, and 3) translate this knowledge into the clinic as rapidly as possible for acute myeloid leukemia, acute lymphoblastic leukemia, and myeloproliferative neoplasms. The specific aims of Project 1: Acute Myeloid Leukemia, on which Dr. Tyner will serve as co-project leader, are to 1) identify individualized gene targets and therapies in AML patients; 2) analyze mechanistic etiology of target sensitivity; and 3) validate oncogenic capacity of genetic lesions and clinical efficacy of therapy.

Title of Project or Subproject	Correlation of biomarker change with in vitro sensitivity of primary AML cells to CPI-267203
Source	Constellation Pharmaceuticals
Name of PI	Jeffrey W. Tyner
Role	PI
Grant Number	No Number
Annual Direct Costs	\$38,134
Dates of Proposed Project	6/1/12 - 5/31/13
% Effort	5%
Major Goals of Project	The major goal of this project is to identify a gene expression signature that correlates with and predicts sensitivity of AML blast cells to the BET inhibitor, CPI-267203.

Title of Project or Subproject	Ventana-OHSU P13K Pathway Q-dot Multiplex Panel Feasibility Project Plan
Source	Ventana Medical Systems, Inc.
Name of PI	Tania Vu
Role	Co-Investigator
Grant Number	No Number
Annual Direct Costs	\$5,000
Dates of Proposed Project	6/1/12 - 5/31/13
% Effort	0%
Major Goals of Project	The major goal of this project is to optimize immunohistochemical staining techniques. My role is to provide support for silencing and/or inhibition of target genes for validation of staining specificity.

Publications/Creative Work:

Peer-reviewed

1. Zhong J., Kim M.S., Chaerkady R., Wu X., Huang T.C., Getnet D., Mitchell C.J., Palapetta S.M., Sharma J., O'Meally R.N., Cole R.N., Yoda A., Moritz A., Loriaux M.M., Rush J., Weinstock D.M., **Tyner J.W.**, and A. Pandey. TSLP signaling network revealed by SILAC-based phosphoproteomics. *Mol Cell Proteomics* Epub ahead of print (2012).

2. Chan D. *, **Tyner J.W.** *, Chng W.J., Bi C., Okamoto R., Said J., Ngan B.D., Braunstein G.D., and H.P. Koeffler. Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. *Oncology Letters* in press (2012).

*** Denotes Equal Contribution**

3. Bains T., Heinrich M.C., Loriaux M.M., Beadling C., Nelson D., Warrick A., Neff T.L., **Tyner J.W.**, Dunlap J., Corless C.L., and G. Fan. Newly Described Activating JAK3 Mutations in T-cell Acute Lymphoblastic Leukemia. *Leukemia* Epub ahead of print (2012).

4. Anur P., Yates J.E., Garbati M.R., Vanderwerf S., Keeble W., Rathbun K., Hays L.E., **Tyner J.W.**, Svahn J., Cappelli E., Dufour C., and G.C. Bagby Jr. p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes. *Blood* **119**, 1992-2002 (2012).

5. **Tyner J.W.**, Jemal A.M., Thayer M., Druker B.J., and B.H. Chang. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. *Leukemia* **26**, 623-632 (2012).

6. Glover J.M., Loriaux M., **Tyner J.W.**, Druker B.J., and B.H. Chang. In Vitro Sensitivity to Dasatinib in Lymphoblasts From a Patient With t(17;19)(q22;p13) Gene Rearrangement Pre-B

Acute Lymphoblastic Leukemia. *Pediatr Blood Cancer* Epub ahead of print (2011).

7. Eide C.A., Adrian L.T., **Tyner J.W.**, Mac Partlin M., Anderson D.J., Wise S.C., Smith B.D., Petillo P.A., Flynn D.L., Deininger M.W., O'Hare T., and B.J. Druker. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABL T315I and exhibits a narrow resistance profile. *Cancer Research* **71**, 3189-95 (2011).

8. Gozgit J.M., Wong M.J., Wardwell S., **Tyner J.W.**, Loriaux M.M., Moheemad Q.K., Narasimhan N.I., Shakespeare W.C., Wang F., Druker B.J., Clackson T., and V.M. Rivera. Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies. *Mol Cancer Ther.* **10**, 1028-35 (2011).

9. Lannutti B.J., Meadows S.A., Herman S.E., Kashishian A., Steiner B., Johnson A.J., Byrd J.C., **Tyner J.W.**, Loriaux M.M., Deininger M., Druker B.J., Puri K.D., Ulrich R.G., and N.A. Giese. CAL-101, a p110 $\{\delta\}$ selective phosphatidylinositol-3-kinase inhibitor (PI3K) for the treatment of B cell malignancies inhibits PI3K signaling and cellular viability. *Blood* **117**, 591-594 (2011).

10. **Tyner J.W.**, Fletcher L.B., Wang E.Q., Yang W.F., Rutenberg-Schoenberg M.L., Beadling C., Mori M., Heinrich M.C., Deininger M.W., Druker B.J., and M.M. Loriaux. MET sequence variants R970C and T992I lack transforming capacity. *Cancer Research* **70**, 6233-7 (2010).

11. **Tyner J.W.**, Bumm T.G., Deininger J., Wood L., Aichberger K.J., Loriaux M.M., Druker B.J., Burns C.J., Fantino E., and M.W. Deininger. CYT387, A Novel JAK2 Inhibitor, Induces Hematologic Responses And Normalizes Inflammatory Cytokines In Murine Myeloproliferative Neoplasms. *Blood*. **115**, 5232-40 (2010).

12. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., Adrian L.T., Zhou T., Huang W.S., Xu Q., Metcalf C.A. 3rd, **Tyner J.W.**, Loriaux M.M., Corbin A.S., Wardwell S., Ning Y., Keats J.A., Wang Y., Sundaramoorthi R., Thomas M., Zhou D., Snodgrass J., Commodore L., Sawyer T.K., Dalgarno D.C., Deininger M.W., Druker B.J., and T. Clackson. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. *Cancer Cell* **16**, 401-12 (2009).

13. Demehri S., O'Hare T., Eide C.A., Smith C.A., **Tyner J.W.**, Druker B.J. and M.W.N. Deininger. The Function of the Pleckstrin Homology (PH) Domain In BCR-ABL-Mediated Leukomogenesis. *Leukemia* **24**, 226-229 (2010).

14. **Tyner J.W.**, Deininger M.W., Loriaux M.M., Chang B.H., Gotlib J.R., Willis S.G., Erickson H., Kovacsovics T., O'Hare T., Heinrich M.C., and B.J. Druker. RNAi Screen for Rapid Therapeutic Target Identification in Leukemia Patients. *PNAS* **106**, 8695-8700 (2009).

15. **Tyner J.W.**, Rutenberg-Schoenberg M.L., Erickson H., Willis S.G., O'Hare T., Deininger M.W., Druker B.J., and M. M. Loriaux. Functional Characterization of an Activating TEK Mutation in Acute Myeloid Leukemia; a Cellular Context-Dependent Activating Mutation. *Leukemia* **23**, 1345-1348 (2009).
16. **Tyner J.W.**, Erickson H., Deininger M.W., Willis S.G., Eide C.A., Levine R.L., Heinrich M.C., Gattermann N., Gilliland D.G., Druker B.J., and M.M. Loriaux. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. *Blood* **113**, 1749-1755 (2009).
17. **Tyner, J.W.**, Loriaux, M.M., Erickson, H., Eide, C.A., Deininger, J., Macpartlin, M., Willis, S.G., Lange, T., Druker, B.J., Kovacsovics, T., Maziarz, R., Gattermann, N., and M.W. Deininger. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. *Leukemia* **23**, 406-409 (2009).
18. Chou C.J., O'Hare T., Lefebvre S., Alvarez D., **Tyner J.W.**, Eide C.A., Druker B.J., and J.M. Gottesfeld. Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate. *PLoS ONE* **3**, e3593 (2008).
19. Kim, E.Y., Battaile, J.T., Patel, A.C., You, Y., Agapov, E., Grayson, M.H., Benoit, L.A., Byers, D.E., Alevy, Y., Tucker, J., Swanson, S., Tidwell, R., **Tyner, J.W.**, Morton, J.D., Castro, M., Polineni, D., Patterson, G.A., Schwendener, R.A., Allard, J.D., Peltz, G., and M.J. Holtzman. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. *Nature Medicine* **14**, 633-640 (2008).
20. O'Hare, T., Eide, C. A., **Tyner, J. W.**, Corbin A. S., Wong, M. J., Buchanan, S., Holme, K., Jessen, K. A., Tang, C., Lewis, H. A., Romero, R. D., Burley, S. K., and M. W. Deininger. SGX393 inhibits the CML mutant Bcr-Abl^{T315I} and preempts *in vitro* resistance when combined with nilotinib or dasatinib. *PNAS* **105**, 5507-5512 (2008).
21. Loriaux, M. M., Levine, R. L., **Tyner, J. W.**, Fröhling, S., Scholl, C., Stoffregen, E. P., Wernig, G., Erickson, H., Eide, C. A., Berger, R., Bernard, O. A., Griffin, J. D., Stone, R. M., Lee, B., Meyerson, M., Heinrich, M. C., Deininger, M. W., Gilliland, D. G., and B. J. Druker. High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia. *Blood* **111**, 4788-4796 (2008).
22. **Tyner, J. W.**, Walters, D. K., Willis, S. G., Luttrupp, M., Oost, J., Loriaux, M., Erickson, H., Corbin, A. S., O'Hare, T., Heinrich, M. C., Deininger, M. W., and B. J. Druker. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. *Blood* **111**, 2238-2245 (2008).

23. Gu T. *, Mercher T. *, **Tyner J.W.***, Goss V.L., Walters D.K., Cornejo M., Reeves C., Popova L., Lee K., Rush J., Comb M.J., Gilliland D.G., Druker B.J., and R.D. Polakiewicz. A Novel Fusion of *RBM6* to *CSF1R* in Acute Megakaryoblastic Leukemia. *Blood*. **110**, 323-333 (2007).

***Denotes Equal Contribution**

24. Schittenhelm M.M., Yee K.W.H., **Tyner J.W.**, McGreevey L., Haley A.D., Town A., Griffith D.J., Bainbridge T., Braziel R.M., O'Farrell A., Cherrington J.M., and M.C. Heinrich. FLT3 K663Q is a Novel AML-associated Oncogenic Kinase: Determination of biochemical properties and sensitivity to SU11248. *Leukemia*. **20**, 2008-2014 (2006).

25. Walters D.K., Mercher T., Gu T., O'Hare T., **Tyner J.W.**, Loriaux M., Goss V.L., Lee K.A., Eide C.A., Wong M.J., Stoffregen E.P., McGreevey L., Nardone J., Moore S.A., Crispino J., Boggon T., Heinrich M.C., Deininger M.W., Polakiewicz R.D., Gilliland D.G., and B.J. Druker. Activating Alleles of *JAK3* in Acute Megakaryoblastic Leukemia. *Cancer Cell* **10**, 65-75 (2006).

26. **Tyner, J.W.**, Kim, E.Y., Ide, K., Pelletier, M.R., Roswit, W.T., Morton, J.D., Castro, M., Spoor, M.S., You, Y., Brody, S.L. and M.J. Holtzman. Pharmacologic targeting of EGFR anti-apoptotic and IL-13 transdifferentiation signals to correct epithelial remodeling in a model of chronic asthma/bronchitis. *Journal of Clinical Investigation* **116**, 309-321 (2005).

27. **Tyner, J.W.**, Uchida, O., Kajiwara, N., Kim, E.Y., Patel, A.C., O'Sullivan, M.P., Walter, M.J., Schwendener, R.A., Cook, D.N., Danoff, T.M., and M.J. Holtzman. CCL5/CCR5 interaction provides anti-apoptotic signals for macrophage survival during viral infection. *Nature Medicine* **11**, 1180-1187 (2005).

Non-peer-reviewed

1. Fleischman A.G. and **J.W. Tyner**. JAK2 V617F down-modulates MPL. *Blood* **17**, 4579-4580 (2012).

2. **Tyner J.W.** Phosphoproteomics microarray screen reveals novel interaction between MPL and Tensin2: Implications for biology, disease and therapeutics. *Cell Cycle* **10**, 2621 (2011).

3. **Tyner J.** and B.J. Druker. RNAi Screen for Therapeutic Target in Leukemia. *Cell Cycle* **8**, 2144 (2009).

4. O'Sullivan, M.P., **Tyner, J.W.** and M.J. Holtzman. Apoptosis in the airways: another balancing act in the epithelial program. *Am J Respir Cell Mol Biol* **29**, 3-7 (2003).

Reviews

1. **Tyner J.W.** Rapid identification of therapeutic targets in hematologic malignancies via functional genomics. *Therapeutic Advances in Hematology* **2**, 83-93 (2011).

2. Holtzman, M.J., Kim, E.Y., Lo, M., **Tyner, J.W.**, Shornick, L.P., Sumino, K.C. and Y. Zhang. Defining and adjusting divergent host responses to viral infection. *Immunol. Res.* **32**, 123-42 (2005).

3. Holtzman, M.J., **Tyner, J.W.**, Kim, E.Y., Patel, A.C., Grayson, M.H., Shornick, L.P., Sumino, K.C., Agapov, E. and Y. Zhang. Acute and chronic airway responses to viral infection: implications for asthma and chronic bronchitis/COPD. *Proc. Am. Thorac. Soc.* **2**, 132-40 (2005).

4. Holtzman, M.J., Shornick L.P., Grayson M.H., Kim E.Y., **Tyner J.W.**, Patel A.C., Agapov E., and Y. Zhang. "Hit-and-run" effects of paramyxoviruses as a basis for chronic respiratory disease. *Pediatr Infect Dis J* **23**, S235-45 (2004).

5. Holtzman, M.J., Morton J.D., Shornick L.P., **Tyner J.W.**, O'Sullivan M.P., Antao A., Lo M., Castro M. and M.J. Walter. Immunity, inflammation, and remodeling in the airway epithelial barrier: epithelial-viral-allergic paradigm. *Physiol Rev* **82**, 19-46. (2002).

Abstracts

Chang, B.H., Jemal, A., **Tyner, J.W.**, Thayer, M. Muschen, M., and B.J. Druker. YM155 Sensitivity in Pediatric Acute Lymphoblastic Leukemia. Abstract in *J Clin Oncol* **30**, suppl; abstr 9555 (2012) .

Bicocca V.T., Chang B.H., Muschen M., Druker B.J. and **J.W. Tyner**. Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia. Abstract in *Blood* (2011).

Fleischman A.G., Sanda T., Gutierrez A., Luty S.B., Willis S.G., Look A.T., Druker B.J. and **J.W. Tyner**. Mutationally Activated TYK2 From T-ALL Specimens Exhibits Transformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice. Abstract in *Blood* (2011).

Hornick N., Huan J., **Tyner J.W.** and P. Kurre. Flt3 Kinase Regulates Microvesicle Transfer of miRNA Between AML and Stromal Cells. Abstract in *Blood* (2011).

Jemal A., **Tyner J.W.**, Thayer M., Muschen M., Druker B.J. and B.H Chang. Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia. Abstract in *Blood* (2011).

Prins R.C., Spurgeon S., **Tyner J.W.**, Fletcher L.B., Jemal A., Bryant J.A., Burke R.T., Chang B.H., Kovacovics T., Druker B.J. and M.M. Loriaux. CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies. Abstract in *Blood* (2011).

Yu Q, Eiring A.M., Zabriskie M.S., Khorashad J., Anderson D.J., Bryant J.A., Loriaux M.M.,

Tyner J.W., O'Hare T. and M.W. Deininger. Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib Abstract in *Blood* (2011).

Mori M., Chen Y., Park B.S., **Tyner J.**, Loriaux M., Kovacsovics T., Druker B. Statistical Issues in Evaluating the Efficacy of Personalized Medicine. 2011 KSS International Conference on Statistics and probability - 40th Anniversary of the Korean Statistical Society, Busan, KOREA, July 1, 2011. <http://www.kss-icsp2011.org/main/>

Mori M., Chen Y., Park B.S., **Tyner J.**, Loriaux M., Kovacsovics T., Druker B. Phase II trial designs to evaluate clinical efficacy of personalized drug selection based on an in vitro sensitivity screen. Joint Statistical Meetings, Miami, Florida, August 1, 2011.

Glover J., Chang B., **Tyner J.**, and B. Druker. Exploring Novel Targets in the Tyrosine Kinase Family in Neuroblastoma. *ASPHO* (2011).

Sanda T., **Tyner J.W.**, Gutierrez A., Ngo V.N., Moriggl R., Ahn Y., Glover J., Chang B.H., Willis S.G., Zhou W., Gray N.S., Staudt L.M., Druker B.J., and A.T. Look. Pathway dependence on the tyrosine kinase TYK2 in T-cell acute lymphoblastic leukemia. *AACR* (2011).

Tyner, J.W., Spurgeon, S., Fletcher, L.B., Yang, W., Kovacsovics, T., Druker, B.J. and M.M. Loriaux. A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias. Abstract in *Blood* (2010).

Tyner, J.W., Tardi, P., Mayer, L., Fletcher L.B., Spurgeon, S., Kovacsovics, T. and M.M. Loriaux. Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells. Abstract in *Blood* (2010).

Bicocca, V., Chang, B.H., Muschen, M., Druker, B.J. and **J.W. Tyner**. ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic Leukemia. Abstract in *Blood* (2010).

Sanda, T., **Tyner, J.W.**, Gutierrez, A., Ngo, V.N., Moriggl R., Ahn, Y., Glover, J.M., Chang, B.H., Willis, S.G., Staudt, L.M., Druker, B.J. and Look, A.T. Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia. Abstract in *Blood* (2010).

Chang, B.H., **Tyner, J.W.**, Jemal, A., Thayer, M. and B.J. Druker. RNAi Identifies Survivin as a Potential Target for Therapy In Pediatric Acute Lymphoblastic Leukemia. Abstract in *Blood* (2010).

Fletcher, L.B., Spurgeon, S., **Tyner, J.W.**, Druker, B.J. and M.M. Loriaux. A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells. Abstract in *Blood* (2010).

Spurgeon, S., Fletcher, L.B., **Tyner, J.W.**, Druker, B.J., Pandey, A., Sinha, U. and M.M. Loriaux. P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations. Abstract in *Blood* (2010).

Tyner J.W., Fletcher L., Yang W., Oh S.T., Gotlib J.R., Deininger M.W., Druker B.J., and M. Loriaux. Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis. Abstract in *Blood* (2009).

Tyner J.W., Loriaux M.M., Willis S.G., Chang B.H., Bicocca V.T., Oh S.T., Hollink I.H.I.M., Segers S., Den Boer M.L., van den Heuvel-Eibrink M.M., Zwaan C.M., Gotlib J.R., Deininger M., and B.J. Druker. RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies. Abstract in *Blood* (2009).

Praveen A., **Tyner J.W.**, Vanderwerff S., Keeble W. and G.C. Bagby Jr. A High Throughput Small Molecule Screening Method for Fanconi Anemia. Abstract in *Blood* (2009).

Tyner J.W., Erickson H., Oh S., Gotlib J.R., Deininger M.W., Druker B.J., and M. Loriaux. Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis. Abstract in *Blood*, **112** 874 (2008).

Bumm T.G.P., **Tyner J.W.**, Deininger J., Loriaux M., VanDyke J., Druker B.J., Burns C.J., Fantino E., and M.W. Deininger. Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD. Abstract in *Blood*, **112** 316 (2008).

O'Hare T., Eide C.A., **Tyner J.W.**, Corbin A.S., Wong M.J., Buchanan S., Holme K., Jessen K.A., Tang C., Lewis H.A., Romero R.D., Burley S.K., and M.W. Deininger. SGX70393 Inhibits Bcr-Abl^{T315I} In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib. Abstract in *Blood*. **110**, 164a (2007).

Loriaux, M. M., Levine, R. L., **Tyner, J. W.**, Fröhling, S., Scholl, C., Stoffregen, E. P., Wernig, G., Erickson, H., Eide, C. A., Berger, R., Bernard, O. A., Griffin, J. D., Stone, R. M., Meyerson, M., Heinrich, M. C., Deininger, M. W., Gilliland, D. G., and B. J. Druker. High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia. Abstract in *Blood*. **110**, 271a (2007).

Agarwal A., Eide C.A., Harlow A., **Tyner J.W.**, Mauro M.J., Corless C.L., Heinrich M.C., Druker B.J., and M.W. Deininger. An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia. Abstract in *Blood*. **110**, 305a (2007).

Tyner J.W., Eide C.A., Stoffregen E.P., Loriaux M., Willis S.G., Gattermann N., Kovacsovics T., Druker B.J., and M.W. Deininger. Identification of tyrosine kinase mutations by large-Scale DNA

Sequencing in Patients with Chronic Myelomonocytic Leukemia/atypical chronic myeloid leukemia. Abstract in *Blood*. **108**, 1030a (2006).

O'Hare T.O., Eide C.A., **Tyner J.W.**, Wong M.J., Smith C.A., Corbin A.S., Buchanan S., Jessen K.A., Tang C., Holme K., Burley S.K., and M.W. Deininger. Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393. Abstract in *Blood*. **108**, 400a (2006).

Tyner, J.W., Uchida, O., Kajiwara, N., Kim, E.Y., O'Sullivan, M.P., Walter, M.J., Cook, D.N., Danoff, T.M., and M.J. Holtzman. Chemokine CCL5 signals required for survival during viral infection. Abstract in *Journal of Allergy and Clinical Immunology*. **113**, S49 (2004).

Invited Lectures, Conference Presentations or Professorships:

International and National

November 29, 2011. Invited Lecture: NIH Cell Biology/Cell Signaling Stadtman Mini-Symposium, Bethesda, MD.

June 27, 2011. Invited Lecture: Blueprint Medicines, Boston, MA.

February 24, 2011. Invited Lecture: Hamon Center for Therapeutic Oncology Research & Simmons Cancer Center Molecular Therapeutics of Cancer Program; UT-Southwestern, Dallas, TX.

Tyner, J.W., Sanda, T., Gutierrez, A., Glover, J.M., Chang, B.H., Willis, S.G., Ahn, Y., Look, A.T. and B.J. Druker. RNAi Screen Reveals TYK2 as a Novel Therapeutic Gene Target In T-Cell Acute Lymphoblastic Leukemia. Abstract in *Blood*, **116**, 1001 (2010).

September 27, 2010. Invited Lecture: City of Hope Comprehensive Cancer Center Seminar Series, Duarte, CA.

March 31, 2010. Invited Lecture: Novartis, Emeryville, CA.

Tyner J.W., Loriaux M.M., Willis S.G., Chang B.H., Bicocca V., Deininger M.W., and B.J. Druker. RAPID siRNA Screen For Identification Of Therapeutic Gene Targets In Patients With Hematologic Malignancies. Myeloid Development Workshop, ASH 2009.

Tyner J.W., Loriaux M.M., Willis S.G., Chang B.H., Bicocca V., Deininger M.W., and B.J. Druker. RAPID siRNA Screen For Identification Of Therapeutic Gene Targets In Patients With Hematologic Malignancies. Joint Symposium of the OTS-ASJ. Fukuoka, Japan. November, 2009.

Tyner J.W., Loriaux M.M., Willis S.G., Chang B.H., Bicocca V., Oh S., Hollink I., Segers S., den Boer M., Zwaan C.M., Gotlib J.R., Deininger M.W., and B.J. Druker. RNAi Screening of the

Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients. Abstract in *Blood*, **112**, 281 (2008).

Tyner J.W., Willis S., Deininger M.W., and B.J. Druker. RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients. ASH 2007. Abstract in *Blood*. **110**, 69a (2007).

Regional and Local

September 26, 2011. Invited Lecture, OHSU Pediatric Cancer Biology Program Retreat, Portland, OR.

June 21, 2011. Invited Lecture, Knight Translational Retreat, Portland, OR.

May 6, 2010. Invited Lecture, Knight Hematologic Malignancies Retreat, Newberg, OR.

September 24, 2009. Oral Presentation at annual Oregon Clinical and Translational Research Institute (OCTRI) Awards Dinner, Portland, OR.

V. SERVICE

Membership in Professional Societies:

2010 American Society of Hematology
2012 Editorial Board, *Clinical Cancer Research*

Granting Agency Review Work:

2012 - The Leukemia & Lymphoma Society Translational Research Program Review Committee

Editorial and Ad Hoc Review Activities:

Ad Hoc Reviewer for *Blood*, *Cancer Research*, *Clinical Cancer Research*, *Leukemia*, *Cancer Cell*, *Nature Genetics*, *Journal of Clinical Investigation*, *American Journal of Respiratory Cell and Molecular Biology*, *Leukemia Research*, *Current Cancer Drug Targets*, *Journal of Pediatric Hematology and Oncology*, *International Journal of Cancer*, and *PLoS ONE*

Ad Hoc Reviewer for: WWTF Science and Technology Fund and Knight Cancer Institute Cancer Research Development Awards

Judge for Oregon Health & Science University Student Research Forum 2009-2011

Committees:

Institutional

Co-PI of T-32 HL07781: Training Program in Molecular Hematology	2010-present
Scholarly Oversight Committee, Jason Glover	2009-2011
Thesis Advisory Committee, Vincent T. Bicocca	2010-present
Thesis Advisory Committee (Chair), Alison Macleod	2011-present

Scholarly Oversight Committee, Nameeta Richard 2011-present
Scholarly Oversight Committee, Lara Davis 2011-present

Departmental

Hematology & Medical Oncology Research Mentoring Committee 2011-present

Honors and Awards for Education

Departmental

2000-2004 Pre-Doctoral Trainee, NIH Training Grant for Pulmonary—Washington University
in St. Louis

2005-2007 Post-Doctoral Trainee, NIH Training Grant for Cancer Research—Oregon Health
& Science University

Institutional

2009 Recipient of Knight Cancer Institute Career Development Award

Regional/National

2010 Recipient of NIH/NCI K99/R00 Career Development Award